Real-world use of MabThera (rituximab) as an induction treatment for patients with ANCA-associated vasculitis (AAV) on low-dose prednisone led…
Articles by José Lopes, PhD
ANCA-associated vasculitis (AAV) diagnoses increased and overall and renal survival improved over a period of 23 years, a real-world study…
A significant proportion of patients who test positive for antibodies associated with ANCA-associated vasculitis (AAV) do not have the…
Glomerular filtration rate (GFR), a kidney function marker, and the presence of atrophy in the kidney’s tubules predict renal survival…
Patients with ANCA-associated vasculitis (AAV) carrying specific variants of the glucocorticoid receptor (GR) gene NR3C1 have a greater…
Plasma exchange — a procedure that removes plasma from the blood and replaces it with a donor-derived substitute — does…
A new classification system of types of glomerular lesions in the kidney enables better prediction of renal function and survival…
An individually tailored treatment with Rituxan (rituximab) is as effective as the standard fixed-schedule regimen in preventing relapses over…
Patients with ANCA-associated vasculitis (AAV) with elevated SDMA — a pro-inflammatory molecule — in their blood have a greater risk of…
The U.S Food and Drug Administration (FDA) cleared two assays to be used in the diagnosis of ANCA-associated vasculitis…